Search Results - "Fernández‐Bolaños, Ricardo"
-
1
Important Role of Oxidative Stress Biomarkers in Huntington’s Disease
Published in Journal of medicinal chemistry (11-08-2011)“…This study examined global oxidative stress (GOS) and antioxidant system and their correlation with disease stage in 19 patients with HD. The results revealed…”
Get full text
Journal Article -
2
Electrolytes Disturbances and Seizures
Published in Epilepsia (Copenhagen) (01-12-2006)Get full text
Journal Article -
3
Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease
Published in Neurological research (New York) (01-09-2012)“…Objectives: Huntington's disease (HD) is a neurodegenerative disorder for which there is no effective treatment. Oxidative stress and inflammation are known to…”
Get full text
Journal Article -
4
NGF and nitrosative stress in patients with Huntington's disease
Published in Journal of the neurological sciences (15-04-2012)“…Abstract Introduction Huntington's disease (HD) is a neurodegenerative genetic disorder caused by expansion of polyglutamine repeats in the huntingtin gene and…”
Get full text
Journal Article -
5
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis
Published in Journal of neurology, neurosurgery and psychiatry (01-12-2016)“…BackgroundAge at onset (AAO) in multiple sclerosis (MS) is an important marker of disease severity and may have prognostic significance. Understanding what…”
Get full text
Journal Article -
6
Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
Published in Annals of neurology (01-03-2015)“…Objective Progressive multifocal leukoencephalopathy (PML) is a serious side effect associated with natalizumab treatment in multiple sclerosis (MS). PML risk…”
Get full text
Journal Article -
7
Predictors of disability worsening in clinically isolated syndrome
Published in Annals of clinical and translational neurology (01-05-2015)“…Objective To assess demographic, clinical, magnetic resonance imaging, and treatment exposure predictors of time to 3 or 12‐month confirmed disability…”
Get full text
Journal Article -
8
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Published in Neurology (05-09-2017)“…OBJECTIVE:To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS)…”
Get full text
Journal Article -
9
Defining reliable disability outcomes in multiple sclerosis
Published in Brain (London, England : 1878) (01-11-2015)“…Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. The disability outcomes used in…”
Get full text
Journal Article -
10
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
Published in Annals of neurology (01-03-2015)“…Objective In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to…”
Get full text
Journal Article -
11
Comparison of first-line fingolimod efficacy compared with first-line interferon-beta or glatiramer therapy in MS patients with active disease using propensity-matched registry data (P3.247)
Published in Neurology (06-04-2015)“…Abstract only…”
Get full text
Journal Article -
12
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
Published in JAMA neurology (01-04-2015)“…After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the…”
Get more information
Journal Article -
13
Predictors and dynamics of postpartum relapses in women with multiple sclerosis
Published in Multiple sclerosis (01-05-2014)“…Background: Several studies have shown that pregnancy reduces multiple sclerosis (MS) relapses, which increase in the early postpartum period. Postpartum…”
Get full text
Journal Article -
14
Prognostic indicators in pediatric clinically isolated syndrome
Published in Annals of neurology (01-05-2017)“…Objective To assess prognostic factors for a second clinical attack and a first disability‐worsening event in pediatric clinically isolated syndrome (pCIS)…”
Get full text
Journal Article -
15
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Published in Multiple sclerosis (01-04-2016)“…Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence…”
Get full text
Journal Article -
16
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
Published in Neurology (02-02-2021)“…To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in…”
Get full text
Journal Article -
17
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome
Published in PloS one (29-06-2012)“…We conducted a prospective study, MSBASIS, to assess factors leading to first treatment discontinuation in patients with a clinically isolated syndrome (CIS)…”
Get full text
Journal Article -
18
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Published in JAMA neurology (01-07-2023)“…Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). To compare the effectiveness of…”
Get more information
Journal Article -
19
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Published in Brain (London, England : 1878) (01-09-2020)“…In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the…”
Get full text
Journal Article -
20
HLA-DRB1 typing in Caucasians patients with neuromyelitis optica
Published in Revista de neurologiá (01-08-2011)“…The existence of antibodies to aquaporin-4 (AQP-4-ab) has identified neuromyelitis optica (NMO) and multiple sclerosis (MS) as different diseases. Although…”
Get full text
Journal Article